These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 10611618)

  • 1. Resampling-based methods for the analysis of multiple endpoints in clinical trials.
    Reitmeir P; Wassmer G
    Stat Med; 1999 Dec; 18(24):3453-62. PubMed ID: 10611618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A note on one-sided tests with multiple endpoints.
    Perlman MD; Wu L
    Biometrics; 2004 Mar; 60(1):276-9; discussion 279-80. PubMed ID: 15032799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Power and sample size for clinical trials when efficacy is required in multiple endpoints: application to an Alzheimer's treatment trial.
    Xiong C; Yu K; Gao F; Yan Y; Zhang Z
    Clin Trials; 2005; 2(5):387-93. PubMed ID: 16317808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Properties of multiple intersection-union tests for multiple endpoints in combination therapy trials.
    Westfall PH; Ho SY; Prillaman BA
    J Biopharm Stat; 2001; 11(3):125-38. PubMed ID: 11725927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One-sided tests in clinical trials with multiple endpoints.
    Bloch DA; Lai TL; Tubert-Bitter P
    Biometrics; 2001 Dec; 57(4):1039-47. PubMed ID: 11764242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A reviewer's perspective on multiple endpoint issues in clinical trials.
    Huque MF; Sankoh AJ
    J Biopharm Stat; 1997 Nov; 7(4):545-64. PubMed ID: 9358328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applying univariate vs. multivariate statistics to investigate therapeutic efficacy in (pre)clinical trials: A Monte Carlo simulation study on the example of a controlled preclinical neurotrauma trial.
    Todorov H; Searle-White E; Gerber S
    PLoS One; 2020; 15(3):e0230798. PubMed ID: 32214370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A combined superiority and non-inferiority approach to multiple endpoints in clinical trials.
    Bloch DA; Lai TL; Su Z; Tubert-Bitter P
    Stat Med; 2007 Mar; 26(6):1193-207. PubMed ID: 16791905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient Monte Carlo evaluation of resampling-based hypothesis tests with applications to genetic epidemiology.
    Fung WK; Yu K; Yang Y; Zhou JY
    Stat Methods Med Res; 2018 May; 27(5):1437-1450. PubMed ID: 27507290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Some comments on frequently used multiple endpoint adjustment methods in clinical trials.
    Sankoh AJ; Huque MF; Dubey SD
    Stat Med; 1997 Nov; 16(22):2529-42. PubMed ID: 9403954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prescott tests of equality in binary data under a three-treatment three-period crossover design.
    Zhu L; Lui KJ
    J Biopharm Stat; 2017; 27(5):834-844. PubMed ID: 27936352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weighted multiple testing correction for correlated tests.
    Xie C
    Stat Med; 2012 Feb; 31(4):341-52. PubMed ID: 22114000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A power study of a sequential method of p-value adjustment for correlated continuous endpoints.
    Arani RB; Chen JJ
    J Biopharm Stat; 1998 Nov; 8(4):585-98. PubMed ID: 9855036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evaluation of multiple surrogate endpoints.
    Xu J; Zeger SL
    Biometrics; 2001 Mar; 57(1):81-7. PubMed ID: 11252622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methods for the analysis of multiple endpoints in small populations: A review.
    Ristl R; Urach S; Rosenkranz G; Posch M
    J Biopharm Stat; 2019; 29(1):1-29. PubMed ID: 29985752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gatekeeping procedures in dose-response clinical trials based on the Dunnett test.
    Dmitrienko A; Offen W; Wang O; Xiao D
    Pharm Stat; 2006; 5(1):19-28. PubMed ID: 17080925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
    Schmidt R; Burkhardt B; Faldum A
    Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of two treatments in the presence of competing risks.
    Lyu J; Chen J; Hou Y; Chen Z
    Pharm Stat; 2020 Nov; 19(6):746-762. PubMed ID: 32476264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consistency-ensured parametric tests for critical events of composite endpoints.
    Huque MF; Alosh M; Guerra M
    J Biopharm Stat; 2018; 28(1):82-98. PubMed ID: 29144871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiplicity adjustment for multiple endpoints in clinical trials with multiple doses of an active treatment.
    Quan H; Luo X; Capizzi T
    Stat Med; 2005 Jul; 24(14):2151-70. PubMed ID: 15909290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.